Nivolumab-Induced Pneumonitis in a Patient With Urothelial Cancer

The introduction of immune checkpoint inhibitors has revolutionized cancer treatment. These drugs function by inhibiting the binding of programmed death-1 (PD-1) and its ligand, PD-L1, which inhibits the immune response against cancer cells. Nivolumab is a PD-1 inhibitor that specifically targets th...

Descripción completa

Detalles Bibliográficos
Autores principales: Kasi, Arbab Furquan Ud din, Nagi, Mohammad Imran, Kasi, Burhanuddin A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290746/
https://www.ncbi.nlm.nih.gov/pubmed/37366435
http://dx.doi.org/10.7759/cureus.39511

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290746/
https://www.ncbi.nlm.nih.gov/pubmed/37366435
http://dx.doi.org/10.7759/cureus.39511

Ejemplares similares